Aberrations in the epigenetic landscape have previously been associated with human diseases such as cancer and schizophrenia, and drugs that target epigenetic processes are currently used as therapeutic agents. This article will review the evidence obtained from animal studies indicating that epigenetic processes might regulate long-term pain states and then discuss the possibility that targeting epigenetic mechanisms might be useful for the management of chronic pain.
INTRODUCTION
Since the link between epigenetic mechanisms and the regulation of long-term pain states was first uncovered, the scientific community has been strongly convinced that these mechanisms could explain the transition to and maintenance of chronic pain states [1] [2] [3] [4] . This article first briefly describes the major epigenetic mechanisms investigated so far in the context of pain states, focusing primarily on those mechanisms that can be targeted with currently available drugs. We then review the findings in the field of pain and epigenetics in animal studies, with an emphasis on most recent developments. We finally discuss the possibility of targeting these mechanisms to treat long-lasting pain states.
EPIGENETIC MECHANISMS
Epigenetic processes regulate the compaction of chromatin, the combination of DNA, histones and other proteins that make up chromosomes. The basic building block of chromatin is the nucleosome which consists of 147 bp of DNA folded around histone octamers containing two each of the histones H2A, H2B, H3 and H4. Although it is widely accepted that epigenetic control involves a variety of facets including noncoding RNA activity and retrotransposable elements [5] [6] [7] [8] , two of the most investigated epigenetic mechanisms are posttranslational modifications of histones and methylation of DNA (Fig. 1) . This article will therefore focus on these mechanisms, particularly as they can be targeted with currently available so-called epigenetic drugs, which include US Food and Drug Administration-approved histone deacetylase inhibitors (HDACis) suberanilohydroxamic acid (SAHA) (vorinostat), belinostat, valproic acid and romidepsin (FK-228), and DNA methyltransferase inhibitors (DNMTis) 5-azacytidine and decitabine (5-aza-2 0deoxycytidine) ( Table 1 ).
Histone modifications
Significant regulation of chromatin compaction is exerted by dynamic histone modifications [18, 19] . The highly accessible N-terminal tails of histones are subject to posttranslational modifications especially prevalent at sites on histones H3 and H4. These modifications include lysine acetylation, serine/threonine phosphorylation, lysine/arginine methylation, ubiquitination and ADP-ribosylation. Generally, the presence of electronegative acetyl or phospho groups decreases affinity between histone proteins and negatively charged DNA and are observed when the chromatin is relaxed and the transcriptional machinery ready to engage in active transcription ( Fig. 1 ). However, the complete picture is complex. For example genes can be in a 'poised' state, presenting both 'activating' and 'repressive' marks, and awaiting further cues. Crucially, such states may mark the potential for plasticity.
Specific enzymes are dedicated to imparting and removing histone modifications. For example while histone acetyltransferases (HATs) are responsible for the addition of histone acetyl marks [20] , histone deacetylases (HDACs) remove acetyl modifications [21] . HDACs are divided into four classes, zincdependent classes I (HDAC 1, 2, 3 and 8), II (IIa: HDAC 4, 5, 7 and 9; IIb: HDAC 6 and 10), and IV (HDAC 11), and the nicotinamide adenine dinucleotide-dependent class III (sirtuins) [22] .
DNA methylation
DNA methylation was until recently regarded as fairly static, if not irreversible. However, it is now well accepted that DNA methylation is dynamically regulated in the adult nervous system, and that this may be crucial for synaptic plasticity and memory
KEY POINTS
Animal models have shown that epigenetic processes regulate the expression of pronociceptive genes in the central nervous system after injury and in long-term pain states.
DNMTis and HDACis are global epigenetic tools that can reduce pain behaviour in subsets of animal models of inflammatory and neuropathic pain states.
However, molecular programs engaged following injury are very complex and depend on the injury and each individual.
Therefore, although global epigenetic tools might be used to treat disease states such as cancer that involve broad rearrangement of the epigenome, they might not be suitable for the long-term treatment of chronic pain states.
More subtle approaches such as epigenome precise editing should be investigated for the treatment of chronic pain. Me formation [23] . DNA methylation of cytosines occurs at CpG dinucleotides (but also other dinucleotides such as CpA, CpC or CpT) [24] . The functional consequence of DNA methylation is as complex as that of histone modifications and depends on the surrounding epigenome landscape. However, generally, high levels of methylation in 5 0 regulatory regions usually silence promoter activity by interfering with transcription factor binding. Here, it is important to note that DNA methylation levels are usually high in intergenic regions and repetitive sequences such as long and short interspersed nuclear elements but low in CG-rich promoter sequences. DNA methylation changes in promoter sequences therefore only contribute minimally to global changes in CpG methylation leaving the meaning of a global change in DNA methylation difficult to interpret in terms of its effect on gene expression. The enzymes that mediate DNA methylation are called DNA methyltransferases (DNMTs) and they are all dynamically expressed in postmitotic neurones [25] . DNMT1 ensures that methylation patterns are copied faithfully throughout each cell division, whereas DNMT3a and 3b regulate de-novo DNA methylation in response to environmental factors, therefore encouraging gene silencing [26] . DNA demethylation is a more complex process which has been shown to involve a number of factors such as the Ten-eleven translocation family [27] , the Gadd45 family [28] and the DNMTs themselves [29] .
We have presented here a basic picture of epigenetic processes and marks, but it is important to emphasize that the complete picture is very intricate. Elaborate crosstalk occurs between histone modifications, DNA methylation, the genomic sequence and other signalling processes, and therefore one must remain wary of overly simplistic interpretations of the meaning of individual epigenetic modification [30] .
Epigenomic dysregulation in cancer: therapeutic use of histone deacetylase and dna methyltransferase inhibitors
Epigenomic dysregulation of histone acetylation and DNA methylation is a hallmark of cancer [31] . HDACis have therefore received a lot of attention in drug development for cancer treatment and some are currently used in the clinics to hyper-acetylate histones and favour transcription of tumour suppressor genes [32] (Table 1) . We should point out that their action on histones is nonspecific since they also deacetylate at lysine sites on nonhistone targets. Interestingly, most nonhistone acetylated proteins are relevant for cancer. Aberrant hypermethylation and silencing of tumour suppressor genes are also commonly associated with the development of cancer, and an increasing number of drugs targeting DNMTis have recently been developed working towards better efficacy and stability and decreased toxicity [33] . The DNMTis 5-azacytidine (5-aza) and decitabine (5-aza-2d) are currently used in cancer treatment to promote the expression of tumour suppressor genes (Table 1 ).
Finally, one should bear in mind that HDACis and DNMTis cannot act specifically on selected genes. Indeed, the epigenetic status of one gene is determined by a multitude of epigenetic modifications, all of which also regulate a large number of other genes. As a result, HDACis and DNMTis can induce both tumour suppressor and prometastatic genes.
EPIGENETIC MECHANISMS IN PAIN PROCESSING
Our purpose here is to offer a perspective on the topic. For this, we have categorized animal studies in two groups, those which have looked at changes in epigenetic enzymes and the epigenome, the sum of chemical modifications to the DNA and histones, during the induction and persistent phase of pain states; and those, more relevant to this article, which have investigated the behavioural and molecular effects of treatments targeting epigenetic processes. As mentioned earlier, we have decided here not to refer to noncoding-RNA-related mechanisms. However, we would like to stress that some studies have suggested that changes in these RNAs contribute to pain sensation through molecular signalling and translational regulation of pain-related genes. These studies have been reviewed elsewhere [5] .
Changes in epigenetic processes in pain pathways
The first studies to investigate epigenetic processes examined the expression of key enzymes required for epigenome marks such as DNA methylation and histone modification along the pain pathway, specifically in dorsal root ganglia (DRGs), the dorsal horn and brain following injury (summarized in Table 2 ). Phosphorylation of MeCP2, the preferential DNA methylation reader at CpG sites, was found to be upregulated in the dorsal horn as early as 1 h following complete Freund's adjuvant (CFA) stimulation, indicating an injury-induced dissociation of MeCP2 from methylated DNA [46] . It was subsequently found that spinal MeCP2 expression was temporally regulated for up to 14 days following spared nerve injury (SNI), chronic constriction injury (CCI) and CFA-induced ankle joint inflammation, albeit in different directions [44, 16] . Injuryinduced changes in spinal DNMTs were also reported following CFA ankle joint inflammation and SNI [44] . Other studies also indicated that histone modifying enzymes, such as HDACs and HATs, were temporally regulated after injury in the spinal cord [9,39,40,43 & ,44,45] . However, these studies lacked consensus in the direction of the changes in expression, probably because of the variations in pain models and time points investigated.
Changes in the epigenome landscape, that is histone modifications and DNA methylation, have also been reported in the sciatic nerve [49, 50] [44] [45] [46] 51] as well as, the brain, specifically the nucleus raphe magnus (NRM) [11] , the frontal cortex [47] and the amygdala [48 && ]. Concerning histone modifications, studies have mainly focused on histone acetylation, whether at a global level or at gene specific promoter areas, and Table 2 clearly illustrates the complexity of these changes. Indeed, reports of both increase and decrease in histone acetylation in the promoter area of pronociceptive genes, as well as global changes in the opposite direction than gene specific changes, have been shown [11] . This complex scenario must be born in mind when considering targeting epigenetic mechanisms for pain relief.
Concerning DNA methylation, although a global increase in DNA methylation was shown to occur in the superficial dorsal horn following CCI [16] , a global decrease was reported in the prefrontal cortex and amygdala 6 months following SNI [47] . In the latter study, methylation levels correlated with the degree of hyperalgesia. However, one must remember that the meaning of a global change in DNA methylation is difficult to interpret in term of its effect on gene expression (see 'DNA methylation' section above). In another study, chemically induced diabetes and injection of CFA in the hindpaw were shown to upregulate cystathionine-b-synthase (CBS) in rat DRGs and this correlated with a downregulation of DNA methylation in CBS promoter area [36,37 && ]. CBS contributed to the hypersensitivity seen in both pain models, but surprisingly, in the Could targeting epigenetic processes relieve chronic pain states? Géranton and Tochiki CFA model, the change in DNA methylation was linked to an upregulation of the demethylating agent growth arrest and DNA-damage-inducible protein GADD45 alpha whereas in the diabetes model it was linked to a downregulation of DNMT3a and 3b [36,37 && ]. We would like to mention here that a number of studies have investigated changes in DNA methylation in the context of pain states outside the central nervous system (e.g. in blood, keratinocytes and neural stem cells) (for complete review Bai et al. [1] ). These studies must be interpreted with caution. Indeed, although recent advances seem to indicate that changes in DNA methylation in peripheral tissues may also bear epigenetic changes indicative of central nervous system modifications and relevant to the hypersensitivity [52, 53] , this needs further investigation.
Finally, recent advances in the field come from cell-specific approaches. Indeed, changes in epigenome have been shown within astrocytes, a cell type which we know play an important role in nociceptive transmission [51] . Cell-specific expression of some elements of the epigenetic machinery has also been reported [38] .
Behavioural and molecular effects of targeting histone acetylation and DNA methylation to improve injury-induced hypersensitivity
Targeting histone deacetylases and histone acetyltransferases HDACis have been so far the most used epigenetic drugs in pain studies (Table 3) . Surprisingly, considering the complexity of the findings described above and the lack of isoform specificity by inhibitors ( Table  1) , administration of HDACis has had an overall positive outcome on pain behaviour in persistent pain models. For example, SAHA has been shown to attenuate the hypersensitivity induced by intraplantar CFA, nerve injury and opioids [9,10 & ,12,11]; NRM infusions of trichostatin A (TSA) and SAHA improved the CFA-induced reduction of paw withdrawal latency [11] ; preemptive intrathecal delivery of MS-275 via osmotic minipumps reduced by 50% both the thermal and mechanical hyperalgesia induced by neuropathic injury [14] .
However, HDACis exacerbated the hypersensitivity induced by skin incision and opioid use, whereas HAT inhibitors (HATis; anacardic acid and curcumin, respectively) attenuated the hypersensitivity seen in these models [12, 13] . Anacardic acid and curcumin have also been reported to improve partial sciatic nerve ligation-induced and CCI-induced mechanical and thermal hypersensitivity [41 & ,50] . The evidence appears to indicate that the inconsistency in the ability of HDACis to improve injuryinduced hypersensitivity is likely to be because of the diversity of the molecular programs engaged after injury, which are highly complex and specific to each pain model. Supporting this idea, all studies mentioned above (and in Table 3 ) have attributed the analgesic properties of HDACis and HATis to various molecular mechanisms such as acetylation at specific gene-loci at various points along the pain pathways. For full review of these mechanisms see Géranton and Tochiki [54] .
For example, NRM infusions of TSA and SAHA were shown to block CFA-induced reduction in H3 acetylation at the Gad2 promoter [11] , the gene encoding glutamic acid decarboxylase 65, the enzyme responsible for catalyzing the decarboxylation of glutamate to GABA and CO 2 . This enhancement of GABAergic synaptic function improved the pain behaviour. In contrast, anacardic acid was shown to attenuate partial sciatic nerve ligationinduced upregulation of acetylation of histone H3 at lysine 9 at the macrophage inflammatory protein 2 and CXC chemokine receptor type 2 promoter in the injured sciatic nerve, in neutrophils and macrophages, therefore reducing the upregulation of macrophage inflammatory protein 2 and CXC chemokine receptor type 2 responsible for the hypersensitivity [50] .
Targeting DNA methylation
So far, only two studies have investigated the effects of targeting DNA methylation by antagonizing DNMTs in the context of animal pain models. CCI induced mechanical and thermal hypersensitivity could be attenuated by intrathecally delivered 5-aza that reversed the CCI induced increase in both spinal MeCP2 and global DNA methylation [16] . Recently, 5-aza-2d was also able to reverse the CFA-induced hypermethylation of the miR-219 promoter, a noncoding RNA found to be downregulated following CFA stimulation. Delivery of 5-aza-2d also attenuated the CFA induced mechanical hypersensitivity and reduced spinal c-Fos expression [17 && ].
SHOULD WE TARGET EPIGENETIC MECHANISMS TO TREAT CHRONIC PAIN STATES AND HOW TO PROCEED?
Clinical cases seen in cancer involve broad rearrangements of the epigenome at many genes and therefore global tools such as HDACis or
Could targeting epigenetic processes relieve chronic pain states? Géranton and Tochiki DNMTis might help with these conditions. However, the complexities of the molecular mechanisms involved in the maintenance of long-term pain states might make HDACis and DNMTis inadequate for the treatment of chronic pain. Indeed, as highlighted above, molecular programs engaged after noxious stimulation are highly specific to the injury. Moreover, in the case of humans, individual past experiences will also modify the molecular landscape and ultimately the response to pain [55] . Therefore, targeting enzymes that globally modulate the epigenetic landscape and therefore affect the regulation of a large number of genes might be inadequate for the control of a limited number of gene and the behaviour they govern. It is worthwhile mentioning here that, while we would expect the use of HDACis to affect the expression of a very large number of genes, few studies have actually found that nonselective HDACis upregulate only 2-15% of all genes analysed, with almost equal number of genes upregulated and downregulated [56, 57] . These findings would suggest some specificity in genes targeted by HDACis but these results remain unexplained and warrant further investigation. A more state-of-the-art and specific approach, although currently lacking in clinical application, would be the precise editing of the epigenome itself. This can be achieved using targeted genome engineering technologies such as designer DNA-binding proteins based on transcriptional activator-like effectors and zinc finger proteins. For a concise review of these emerging technologies, refer to Day [58] . These artificial transcription factors are tailored to recognize specific DNA sequences and can be engineered to generate tools for targeted genome modification [59] . They have been used successfully to increase DNA methylation in the promoter sequence of, and therefore silence, oncogenic genes in animal models [60] . One could therefore hypothesize that the precise editing of the epigenome of a number of pronociceptive genes would be a subtle approach for the treatment of chronic pain states.
CONCLUSION
The field of epigenetics and pain is very rapidly emerging, but the complexity of the molecular programs engaged after injury and in long-term pain states remain the main hurdle in the search for novel therapeutic approaches. Although currently available global epigenetic tools such as HDACis might seem worthy of our attention, more precise tools such as artificial transcription factors might become a better option for the long-term treatment of chronic pain states.
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